The company ended both studies after an independent committee, having reviewed all available data, judged it unlikely that the trials would reach a different outcome than another Phase III study that missed its primary endpoint in July, according to reports from outlets including Endpoints News.
In that earlier study, ziltivekimab failed to reduce the risk of major cardiovascular events — death, non‑fatal myocardial infarction and non‑fatal stroke — compared with placebo.
BREAKING